MedTrace Logo

Intravenous Artesunate and Malaria

NCT01805232 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-03-06

No results posted yet for this study

Summary

Intravenous artesunate is egual to quinine in the treatment of severe malaria

Conditions

Interventions

DRUG

artesunate

intravenous artesunate 80 mg/kg initially then after 8 hours then daily

DRUG

Quinine

quinine infusion 80 mg/kg every 8 hours till the patient can take orally

Sponsors & Collaborators

  • University of Kassala, Sudan

    collaborator OTHER

  • Kassala

    collaborator UNKNOWN

  • Sudan

    collaborator UNKNOWN

  • University of Khartoum

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-05-31
Completion
2013-07-31

Countries

  • Sudan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805232 on ClinicalTrials.gov